Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Manuela Farris, Carlo Bastianelli, Elena Rosato, Ivo Brosens & Giuseppe Benagiano. (2019) Uterine fibroids: an update on current and emerging medical treatment options. Therapeutics and Clinical Risk Management 15, pages 157-178.
Read now
Read now
Giuseppe Benagiano, Carlo Bastianelli, Manuela Farris & Ivo Brosens. (2014) Selective progesterone receptor modulators: an update. Expert Opinion on Pharmacotherapy 15:10, pages 1403-1415.
Read now
Read now
Josep Lluis Carbonell Esteve, Rita Acosta, Yasmirian Pérez, Barbara Rodriguez, Isabel Seigler, Carlos Sanchez & Giuseppe Tomasi. (2013) Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. International Journal of Women's Health 5, pages 361-369.
Read now
Read now
Friederike Hoellen, Georg Griesinger & Michael K Bohlmann. (2013) Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opinion on Pharmacotherapy 14:15, pages 2079-2085.
Read now
Read now
Articles from other publishers (11)
Shu-Yi Chen, Meng-Dan Zhao, Wen-Ting Sun, Li-Bo Zhu & Xin-Mei Zhang. (2022) Investigation of the 12-month efficacy and safety of low-dose mifepristone in the treatment of painful adenomyosis. Reproductive and Developmental Medicine 6:3, pages 152-161.
Crossref
Crossref
Richard J. Rovelli, Nicole E. Cieri-Hutcherson & Timothy C. Hutcherson. (2022) Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids. Journal of the American Pharmacists Association 62:3, pages 674-682.e5.
Crossref
Crossref
Md Soriful Islam, Sadia Afrin, Sara Isabel Jones & James Segars. (2020) Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility. Endocrine Reviews 41:5.
Crossref
Crossref
Kiriaki Papaikonomou, Caroline Frisendahl, Alistair R.W. Williams & Kristina Gemzell-Danielsson. (2020) Effects of the levonorgestrel intrauterine system on the endometrium after long-term exposure to mifepristone: Secondary outcomes of a randomized controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology 252, pages 330-335.
Crossref
Crossref
Yanina A. Lebedeva, Evgeniа B. Troik, Oleg L. Molchanov & Yuri N. Fedotov. (2019) Possibilities of applying antigestagens in therapy. Journal of obstetrics and women's diseases 68:2, pages 51-58.
Crossref
Crossref
C. Berger, N. Boggavarapu, E. Norlin, S. Queckbörner, K. Hörnaeus, A. Falk, M. Engman, M. Ramström, P.G.L. Lalitkumar & K. Gemzell-Danielsson. (2018) Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment. Contraception 98:4, pages 317-322.
Crossref
Crossref
Geum Seon SohnSiHyun Cho, Yong Man KimChi-Heum ChoMee-Ran KimSa Ra Lee. (2018) Current medical treatment of uterine fibroids. Obstetrics & Gynecology Science 61:2, pages 192.
Crossref
Crossref
Ally Murji, Lucy Whitaker, Tiffany L Chow & Mara L Sobel. (2017) Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database of Systematic Reviews 2017:4.
Crossref
Crossref
Christian Seitz, Žana Bumbuliene, Ana Rosa Costa, Oskari Heikinheimo, Andrea Heweker, Robert Hudeček, Yves Jacquemyn, Gian Benedetto Melis, Pooja Parashar, Tomasz Rechberger, Antonio Cano Sánchez, Bart van Aken, János Zatik & Kristina Gemzell-Danielsson. (2017) Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemporary Clinical Trials 55, pages 56-62.
Crossref
Crossref
Anupam Kapur, Ranjeeta Angomchanu & Madhusudan Dey. (2016) Efficacy of Use of Long-Term, Low-Dose Mifepristone for the Treatment of Fibroids. The Journal of Obstetrics and Gynecology of India 66:S1, pages 494-498.
Crossref
Crossref
Marta Martín Millán & Santos Castañeda. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
615
634
.